160 related articles for article (PubMed ID: 33200904)
21. Predictive factors for the success of trial without catheter for men with urinary retention.
Takanashi M; Ito H; Fukazawa T; Takizawa H; Hioki M; Shinoki R; Kawahara T; Kobayashi K
Low Urin Tract Symptoms; 2023 Sep; 15(5):173-179. PubMed ID: 37278133
[TBL] [Abstract][Full Text] [Related]
22. Α₁-blockers in the management of acute urinary retention secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.
Guang-Jun D; Feng-Bin G; Xun-Bo J
Ir J Med Sci; 2015 Mar; 184(1):23-30. PubMed ID: 24599498
[TBL] [Abstract][Full Text] [Related]
23. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
McNeill SA; Hargreave TB; Roehrborn CG;
Urology; 2005 Jan; 65(1):83-9; discussion 89-90. PubMed ID: 15667868
[TBL] [Abstract][Full Text] [Related]
24. A prospective pilot study to validate the management protocol for patients presenting with acute urinary retention: a community-based, nonhospitalised protocol.
Gopi SS; Goodman CM; Robertson A; Byrne DJ
ScientificWorldJournal; 2006 Jun; 6():2436-41. PubMed ID: 17619714
[TBL] [Abstract][Full Text] [Related]
25. Is intravesical prostatic protrusion a risk factor for hydronephrosis and renal insufficiency in benign prostate hyperplasia patients?
Lu CH; Wu HHH; Lin TP; Huang YH; Chung HJ; Kuo JY; Huang WJ; Lu SH; Chang YH; Lin ATL
J Chin Med Assoc; 2019 May; 82(5):381-384. PubMed ID: 30893258
[TBL] [Abstract][Full Text] [Related]
26. The Reten-World survey of the management of acute urinary retention: preliminary results.
Emberton M; Fitzpatrick JM
BJU Int; 2008 Mar; 101 Suppl 3():27-32. PubMed ID: 18307683
[TBL] [Abstract][Full Text] [Related]
27. Prostate Artery Embolization for Complete Urinary Outflow Obstruction Due to Benign Prostatic Hypertrophy.
Yu SC; Cho CC; Hung EH; Chiu PK; Yee CH; Ng CF
Cardiovasc Intervent Radiol; 2017 Jan; 40(1):33-40. PubMed ID: 27853823
[TBL] [Abstract][Full Text] [Related]
28. Management outcome of acute urinary retention: model of prediction.
Daly P; Connolly S; Rogers E; Sweeney P
Urol Int; 2009; 83(1):39-43. PubMed ID: 19641357
[TBL] [Abstract][Full Text] [Related]
29. The efficacy of in-and-out catheterization as a way of trial without catheterization strategy for treatment of acute urinary retention induced by benign prostate hyperplasia: variables predicting success outcome.
Ko YH; Kim JW; Kang SG; Jang HA; Kang SH; Park HS; Moon du G; Cheon J; Kim JJ; Lee JG
Neurourol Urodyn; 2012 Apr; 31(4):460-4. PubMed ID: 22331691
[TBL] [Abstract][Full Text] [Related]
30. Does acute urinary retention respond to alpha-blockers alone?
McNeill SA
Eur Urol; 2001 Mar; 39 Suppl 6():7-12. PubMed ID: 11306895
[TBL] [Abstract][Full Text] [Related]
31. Intravesical Prostatic Protrusion as a Predicting Factor for the Adverse Clinical Outcome in Patients With Symptomatic Benign Prostatic Enlargement Treated With Dutasteride.
Yoshida T; Kinoshita H; Yoshida K; Mishima T; Taniguchi H; Yanishi M; Komai Y; Yasuda K; Sugi M; Matsuda T
Urology; 2016 May; 91():154-7. PubMed ID: 26826590
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of Silodosin and Dutasteride Combination Therapy in Acute Urinary Retention due to Benign Prostatic Hyperplasia: A Single-Arm Prospective Study.
Hagiwara K; Koie T; Iwamura H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Ohyama C
Biomed Res Int; 2016; 2016():4975851. PubMed ID: 27195288
[TBL] [Abstract][Full Text] [Related]
33. Systematic review and meta-analysis on management of acute urinary retention.
Yoon PD; Chalasani V; Woo HH
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):297-302. PubMed ID: 26195469
[TBL] [Abstract][Full Text] [Related]
34. Is intravesical prostatic protrusion associated with more complications in benign prostatic hyperplasia patients?
Eze BU; Ani CO; Mbaeri TU
Low Urin Tract Symptoms; 2021 Oct; 13(4):468-474. PubMed ID: 34080315
[TBL] [Abstract][Full Text] [Related]
35. A comparative study on the use of tamsulosin versus alfuzosin in spontaneous micturition recovery after transurethral catheter removal in patients with benign prostatic growth.
Maldonado-Ávila M; Manzanilla-García HA; Sierra-Ramírez JA; Carrillo-Ruiz JD; González-Valle JC; Rosas-Nava E; Guzman-Esquivel J; Labra-Salgado IR
Int Urol Nephrol; 2014 Apr; 46(4):687-90. PubMed ID: 24061764
[TBL] [Abstract][Full Text] [Related]
36. Risk factors for a failed trial without catheter following convective water vapor thermal therapy (CWVTT-Rezum).
Felice MD; Kim K; Janakiraman S; Pahouja G; Adams W; Fruth E; Farooq A; McVary KT
Low Urin Tract Symptoms; 2023 Sep; 15(5):158-164. PubMed ID: 37232068
[TBL] [Abstract][Full Text] [Related]
37. Predicting the risk of failed trial without catheter following Rezum™ therapy.
Coscarella M; Al Barajraji M; Moussa I; Hombert L; Naudin M; Roumeguère T
World J Urol; 2024 Mar; 42(1):129. PubMed ID: 38460028
[TBL] [Abstract][Full Text] [Related]
38. Management of acute urinary retention secondary to benign prostatic hyperplasia in the UK: a national survey.
Manikandan R; Srirangam SJ; O'Reilly PH; Collins GN
BJU Int; 2004 Jan; 93(1):84-8. PubMed ID: 14678374
[TBL] [Abstract][Full Text] [Related]
39. Benign prostatic hyperplasia: mode of presentation and postoperative outcome.
Khan M; Khan AL; Khan S; Nawaz H
J Pak Med Assoc; 2005 Jan; 55(1):20-3. PubMed ID: 15816691
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
